1-20 of 25
Paul B. Chapman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study

James W. Smithy, Hannah L. Kalvin, Fiona D. Ehrich, Ronak Shah, Matthew Adamow, Vladislav Raber, Collen A. Maher, Jenna Kleman, Deborah A.G. McIntyre, Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D. Wolchok, Paul B. Chapman, Michael F. Berger, Katherine S. Panageas, Michael A. Postow
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3407–3415.
https://doi.org/10.1158/1078-0432.CCR-23-3643
Published: 15 August 2024
View article titled, Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Open the PDF for Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study in another window
Includes: Supplementary data
Journal Articles

The State of Melanoma: Emergent Challenges and Opportunities

Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne M. Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2678–2697.
https://doi.org/10.1158/1078-0432.CCR-20-4092
Published: 15 May 2021
View article titled, The State of Melanoma: Emergent Challenges and Opportunities
Open the PDF for The State of Melanoma: Emergent Challenges and Opportunities in another window
Journal Articles

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Alexander N. Shoushtari, Walid K. Chatila, Arshi Arora, Francisco Sanchez-Vega, Havish S. Kantheti, Jorge A. Rojas Zamalloa, Penina Krieger, Margaret K. Callahan, Allison Betof Warner, Michael A. Postow, Parisa Momtaz, Suresh Nair, Charlotte E. Ariyan, Christopher A. Barker, Mary Susan Brady, Daniel G. Coit, Neal Rosen, Paul B. Chapman, Klaus J. Busam, David B. Solit, Katherine S. Panageas, Jedd D. Wolchok, Nikolaus Schultz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-20-4189
Published: 15 April 2021
View article titled, Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Open the PDF for Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas in another window
Includes: Supplementary data
Journal Articles

The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas

Alvin P. Makohon-Moore, Evan J. Lipson, Jody E. Hooper, Amanda Zucker, Jungeui Hong, Craig M. Bielski, Akimasa Hayashi, Collin Tokheim, Priscilla Baez, Rajya Kappagantula, Zachary Kohutek, Vladimir Makarov, Nadeem Riaz, Michael A. Postow, Paul B. Chapman, Rachel Karchin, Nicholas D. Socci, David B. Solit, Timothy A. Chan, Barry S. Taylor, Suzanne L. Topalian, Christine A. Iacobuzio-Donahue
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1516–1525.
https://doi.org/10.1158/1078-0432.CCR-20-2984
Published: 01 March 2021
View article titled, The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Open the PDF for The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas in another window
Includes: Supplementary data
Journal Articles

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Michael A. Postow, Susan J. Knox, Debra A. Goldman, Yuval Elhanati, Vikram Mavinkurve, Phillip Wong, Darragh Halpenny, Sunil K. Reddy, Kenya Vado, Danielle McCabe, Kristen Aufiero Ramirez, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Parisa Momtaz, Alexander N. Shoushtari, Margaret K. Callahan, Paul B. Chapman, Jedd D. Wolchok, Priyanka B. Subrahmanyam, Holden T. Maecker, Katherine S. Panageas, Christopher A. Barker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3193–3201.
https://doi.org/10.1158/1078-0432.CCR-19-3936
Published: 01 July 2020
View article titled, A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Open the PDF for A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3239–3246.
https://doi.org/10.1158/1078-0432.CCR-18-0720
Published: 01 June 2019
View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma
Open the PDF for Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors

Samuel A. Funt, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2323–2328.
https://doi.org/10.1158/1078-0432.CCR-15-1961
Published: 12 May 2016
View article titled, The Role of Neoadjuvant Trials in Drug Development for Solid Tumors
Open the PDF for The Role of Neoadjuvant Trials in Drug Development for Solid Tumors in another window
Journal Articles

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker

Alexia Iasonos, Paul B. Chapman, Jaya M. Satagopan
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2114–2120.
https://doi.org/10.1158/1078-0432.CCR-15-2517
Published: 01 May 2016
View article titled, Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Open the PDF for Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker in another window
Includes: Supplementary data
Journal Articles

Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib

Emily C. Zabor, Glenn Heller, Lawrence H. Schwartz, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1341–1347.
https://doi.org/10.1158/1078-0432.CCR-15-1441
Published: 14 March 2016
View article titled, Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Open the PDF for Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib in another window
Includes: Supplementary data
Journal Articles

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

Ravi K. Amaravadi, Kathryn E. Hamilton, Xiaohong Ma, Shengfu Piao, Armando Del Portillo, Katherine L. Nathanson, Matteo S. Carlino, Georgina V. Long, Igor Puzanov, Xiaowei Xu, Jennifer J.D. Morrissette, Kenneth Y. Tsai, Keith T. Flaherty, Jeffrey A. Sosman, Grant R. Goodman, Grant A. McArthur, Anil K. Rustgi, David C. Metz, Lynn M. Schuchter, Paul B. Chapman, Antonia R. Sepulveda
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5215–5221.
https://doi.org/10.1158/1078-0432.CCR-15-0469
Published: 30 November 2015
View article titled, Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Open the PDF for Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View article titled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2257–2264.
https://doi.org/10.1158/1078-0432.CCR-12-3476
Published: 15 April 2013
View article titled, Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Open the PDF for Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma

Mrinali Patel, Elizabeth Smyth, Paul B. Chapman, Jedd D. Wolchok, Gary K. Schwartz, David H. Abramson, Richard D. Carvajal
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2087–2100.
https://doi.org/10.1158/1078-0432.CCR-10-3169
Published: 14 April 2011
View article titled, Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma
Open the PDF for Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma in another window
Journal Articles

Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

Emanuela Romano, Marco Rossi, Gudrun Ratzinger, Maria-Angeles de Cos, David J. Chung, Katherine S. Panageas, Jedd D. Wolchock, Alan N. Houghton, Paul B. Chapman, Glenn Heller, Jianda Yuan, James W. Young
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1984–1997.
https://doi.org/10.1158/1078-0432.CCR-10-3421
Published: 31 March 2011
View article titled, Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em>
Open the PDF for Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection

Brian A. Ginsberg, Humilidad F. Gallardo, Teresa S. Rasalan, Matthew Adamow, Zhenyu Mu, Sapna Tandon, Barrett B. Bewkes, Ruth-Ann Roman, Paul B. Chapman, Gary K. Schwartz, Richard D. Carvajal, Katherine S. Panageas, Stephanie L. Terzulli, Alan N. Houghton, Jianda D. Yuan, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 4057–4065.
https://doi.org/10.1158/1078-0432.CCR-10-1093
Published: 28 July 2010
View article titled, Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection
Open the PDF for Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Patricia M. LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle M. Nabell, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weiwei Tan, Alejandro D. Ricart
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1924–1937.
https://doi.org/10.1158/1078-0432.CCR-09-1883
Published: 14 March 2010
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers in another window
Journal Articles

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

David B. Solit, Iman Osman, David Polsky, Katherine S. Panageas, Adil Daud, James S. Goydos, Jerrold Teitcher, Jedd D. Wolchok, F. Joseph Germino, Susan E. Krown, Daniel Coit, Neal Rosen, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8302–8307.
https://doi.org/10.1158/1078-0432.CCR-08-1002
Published: 15 December 2008
View article titled, Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
Open the PDF for Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside

Paul B. Chapman, Dianna Wu, Govind Ragupathi, Sharon Lu, Linda Williams, Wen-Jen Hwu, Diantha Johnson, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4717–4723.
https://doi.org/10.1158/1078-0432.CCR-04-0345
Published: 21 July 2004
View article titled, Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside
Open the PDF for Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside in another window
Journal Articles

Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21

Govind Ragupathi, Philip O. Livingston, Chandra Hood, John Gathuru, Susan E. Krown, Paul B. Chapman, Jedd D. Wolchok, Linda J. Williams, Roberta C. Oldfield, Wen-Jen Hwu
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5214–5220.
Published: 12 November 2003
View article titled, Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21
Open the PDF for Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21 in another window
Journal Articles

T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants

Susanne G. Schaed, Virginia M. Klimek, Katherine S. Panageas, Cristina M. Musselli, Leah Butterworth, Wen-Jen Hwu, Philip O. Livingston, Linda Williams, Jonathan J. Lewis, Alan N. Houghton, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 967–972.
Published: 01 May 2002
View article titled, T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle>
Open the PDF for T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle> in another window